Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
Ilaria Grazia Zizzari(Sapienza University of Rome), Chiara Napoletano(Sapienza University of Rome), Andrea Botticelli(Sapienza University of Rome), Francesca Romana Di Pietro(Azienda Ospedaliera Sant'Andrea), Simone Scagnoli(Policlinico Umberto I), Paolo Marchetti(Sapienza University of Rome), Fabio Scirocchi(Moffitt Cancer Center), Alessandra Di Filippo(Sapienza University of Rome), Marianna Nuti(National Institutes of Health), Aurelia Rughetti(Sapienza University of Rome), Hassan Rahimi(Sapienza University of Rome), Lorenza Putignani(Bambino Gesù Children's Hospital), Federica Del Chierico(Bambino Gesù Children's Hospital), Alessio Ugolini(The Wistar Institute), Pamela Vernocchi(Bambino Gesù Children's Hospital)
Cited by 44
Related Papers
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach
|Hepatology|2016|710
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563
The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases
|Microorganisms|2021|336
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations
|International Journal of Cancer|1982|327
Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization
|BMC Microbiology|2011|310